Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
Australia and New Zealand have established themselves as ideal locations to host clinical trials due to their diverse participant populations, sophisticated healthcare and research environments as well as government backed support. Both countries have adopted the International Council for Harmonisation (ICH) Guideline for Good Clinical Practice (GCP) to ensure all trials collect high quality and credible data that is internationally recognised.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing.
Now, three of the largest clinical trial organisations across Australia and New Zealand have united to form Momentum Clinical Research – an end-to-end clinical research network with sites that have been operating for over 20 years. Combined, they have 13 site locations across the Trans-Tasman and are set to open more locations to allow more studies to take place and enable everyday people to access new and emerging therapies.
In February 2024, New Zealand’s renowned P3 Research joined forces with Australia’s AusTrials and Holdsworth House to form Momentum Clinical Research. The combined entity can now provide sponsors a single point of contact for their current 13 sites across the two countries,
Momentum Clinical Research aims to provide quick responses to feasibility requests, faster study starts and accelerated recruitment – all leading to the delivery of high-quality results for Phase 1b-IV clinical trials. Momentum Clinical Research has become the only Trans-Tasman network of clinical trial sites.
Australian Health Journal spoke with Aus Trials Research Director, Dr Munro Neville, on the Australian clinical trial landscape more broadly and reasons for creating a Trans-Tasman clinical research organisation.
Further growth in the industry is expected, with the Australian Government having pledged $750 million to increase clinical trial activity between 2022-2032. Similarly, the New Zealand Government has invested $98 million into health research funding from 2017-2027 to facilitate the conduct of clinical trials.
You Might also like
-
Fulfilling clinical, academic & research goals in General Practice
Dr Ramya Raman is a Specialist General Practitioner, medical educator, and health policy leader. Raised in Orange in Central West NSW, where she lived for over 15 years, she brings a deep, lived understanding of rural and community healthcare to her work.
-
“Nurses can do more, should do more and now they will do more”, The Hon Minister Greg Hunt MP, Minister for Health.
Advanced Practice Nurses comprise 9% of the total nursing workforce, with 26,000 clinicians Australia wide. However although highly skilled, they are under-utilised and constrained to the full scope of practice. The Australian College of Nursing believes this needs to change. Nurse led models of care in which Advanced Practice Nurses play a significant role in service provision, must feature in the future. ACN President Professor Christine Duffield FACN states, “It’s now widely acknowledged internationally that nurses can provide a clinical and very valuable service that’s better suited to the healthcare needs of some consumer groups.”
-
Evolution in consumer diagnostics with saliva based pathology
Since the COVID-19 pandemic, consumer diagnostics have rapidly advanced, with more people becoming aware of and comfortable using at-home testing. These tests provide greater convenience, control, and empowerment, allowing individuals to monitor their health without immediately consulting a healthcare professional. Recently, this shift has been particularly impactful in areas such as pregnancy testing, where saliva-based diagnostics now enable earlier and more accessible detection.